<DOC>
	<DOCNO>NCT00532090</DOCNO>
	<brief_summary>This study determine maximum tolerate dose , safety pharmacokinetic profile R4733 ( RO4929097 ) , administer orally patient refractory metastatic locally advanced solid tumor . The study assess three different dose schedule ; one schedule R4733 administer 3days on/ 4 day , another day 1-7 21 day cycle , third schedule continuously daily . The start dose dose regimen escalate subsequent group patient satisfactory assessment safety tolerability previous dose . The anticipated time study treatment disease progression dose-limiting toxicity , target sample size 100-200 individual .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study R4733 Patients With Advanced Solid Tumors .</brief_title>
	<detailed_description />
	<criteria>adult patient , &gt; =18 year age ; advanced and/or metastatic solid tumor malignancy ; measurable evaluable disease ; ECOG performance status 0 1. prior chemotherapy , radiotherapy immunotherapy within 28 day first receipt study drug ; prior corticosteroid anticancer therapy within minimum 14 day first receipt study drug . Dexamethasone may allow part supportive care measure ; major surgery within 28 day first receipt study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>